Background
==========

Head and neck paragangliomas (HNP) are rare vascular tumors accounting for less than 0.5% of all head and neck tumors \[[@b1-poljradiol-81-510]\]. They are highly vascular neoplasms, mostly benign, but clinical symptoms depend on their size and location. In general, HNP are characterized by a slow rate of growth and, potentially, they remain stable and clinically silent over years. These neuroectodermal tumors arise from a group of tissues (paraganglia) which migrate along the branchiomeric (of the branchial mesoderm) distribution in the head and neck region. Paragangliomas within the head and neck arise mainly from four primary sites: carotid bodies, common carotid artery bifurcation (carotid paragangliomas), jugular foramen (jugular paragangliomas), along the vagus nerve (vagal paragangliomas), and the tympanic branch of the ascending pharyngeal artery within the middle ear (tympanic paragangliomas). Other sites, including the paranasal sinuses, larynx, cervical sympathetic chain, parathyroid gland and thyroid gland are rare \[[@b2-poljradiol-81-510]\].

The majority of paragangliomas evolve sporadically, but one-third to one-half of cases have familial etiology \[[@b3-poljradiol-81-510],[@b4-poljradiol-81-510]\].

Mutations in ten different genes connected with hereditary HNP were found \[[@b2-poljradiol-81-510]\].

Pheochromocytoma-paraganglioma (PGL) syndromes are associated with *SDHx* gene mutations, encoding the subunits of the succinate dehydrogenase enzyme complex, subunit D *(SDHD*), B (*SDHB)* and C (*SDHC*), (PGL type 1,4, and 3, respectively). Recently, germline mutations in two consecutive subunits of succinate dehydrogenase (*SDHA, SDHAF2*) have been found in patients with pheochromocytoma-paraganglioma syndrome \[[@b5-poljradiol-81-510]\]. HNP association with other genetic multisystemic disorders such as von Hippel-Lindau (*VHL*), transmembrane protein 127 (*TMEM 127*), neurofibromatosis type 1 (*NF1*), MYC-associated factor X (*MAX*), protooncogene *RET* occurs rarely \[[@b6-poljradiol-81-510]--[@b9-poljradiol-81-510]\].

Patients with hereditary syndromes are at a higher risk of having multifocal disease \[[@b10-poljradiol-81-510]\].

The aim of this study is to determine the frequency and location of HNP among SDHx carriers.

Material and Methods
====================

Patients
--------

The patients with confirmed *SDHx* mutations by genetic testing entered the study.

This study consisted of 72 patients with *SDXs* mutations (36 men, 36 women, mean age 44±14.26 y, age range 13--74 yrs, 44 index cases, 28 relatives), 23 (31.9%) patients with *SDHB* mutations, 5 (6.9%) with *SDHC* mutations, and 44 (61.1%) with *SDHD* mutations.

Patients with the Polish Pheochromocytoma-Paraganglioma Registry were included in our study. All SDHx germline mutation carriers underwent screening work-up which included computed tomography (CT) of the head and neck.

Clinical characteristics of patients are present in [Table 1](#t1-poljradiol-81-510){ref-type="table"}.

All patients gave their informed consent before participating in the study. The study was approved by the local ethics committee.

Methods
-------

Computed tomography (CT) examinations were performed with a dual source scanner (Somatom Definition or Somatom Flash, Siemens Medical Solution). Head and neck acquisition started after 40s of the contrast medium injection (80--100 mL at a rate of 3.5--4 mL/s) in order to obtain good opacification of both arterial and venous vessels.

The slice thickness was 1 mm, tube voltage was set at 80--120 kV, tube current 165--210 mA.

Contraindications to CT examination included renal insufficiency, hypersensitivity to iodine-containing contrast material and uncontrolled hyperthyroidism.

Soft tissue masses with intense enhancement after i.v. contrast administration in typical locations were recognized as paragangliomas \[[@b11-poljradiol-81-510]\].

The criterion for malignancy were metastases to lymph nodes or distant metastases.

The HNP were classified according to the location: carotid body paragangliomas (located in the common carotid artery bifurcation), jugular paragangliomas (located in the foramen jugular), tympanic paragangliomas (located in the middle ear cavity) and vagal paragangliomas (along the cervical portion of the vagus nerve). Carotid paragangliomas lead to splaying of the carotid arteries, while vagal paragangliomas cause an anterior displacement of the internal carotid artery \[[@b11-poljradiol-81-510]\].

Carotid body paragangliomas were classified according to the Shamblin criteria based on the involvement of the carotid vessels.

1.  Class I -- tumors are localized in the carotid bifurcation with splaying of arteries but the surrounding vessels remain intact.

2.  Class II -- tumors adhere to the carotid vessels or partially surround them.

3.  Class III -- large tumors encase the carotid vessels.

Statistical analysis
--------------------

The data were analyzed using SPSS statistical analysis software version 12.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean ± standard deviation (SD) and compared using 2-tailed, unpaired Student's t-test. Fisher's test and/or Chi-square were used to test for differences in categorical variables. The 2-tailed probability value of p\<0.05 was considered statistically significant.

Results
=======

HNP were present in 44 (61.1%) out of 72 patients (31 *SDHD*, 11 *SDHB*, 2 *SDHC*).

One hundred and thirteen paragangliomas were found in 44 patients; the most common locations were: the carotid bifurcation (59 paragangliomas, [Figure 1](#f1-poljradiol-81-510){ref-type="fig"}) and along the vagal nerve (27 paragangliomas, [Figure 2](#f2-poljradiol-81-510){ref-type="fig"}). Moreover, 14 jugular paragangliomas and 11 tympanic paragangliomas were found. In one case, a paraganglioma was located in the thyroid and, in one case in soft tissues of the neck. [Table 2](#t2-poljradiol-81-510){ref-type="table"} shows the number and locations of paragangliomas in patients with *SDHx* mutations.

The mean dimension of all HNP was 17.9±10.8 mm (dimension range 3--48 mm). The mean dimension of carotid paragangliomas was 17.8±11.1 mm (range 4--42 mm), the jugular paragangliomas 21.6±6.3 mm (range 10--35 mm), vagal paragangliomas 19.6±12.0 (range 6--48 mm) and tympanic paraganglioma 6.7±2.3 mm (range 3--10 mm).

Multiple paragangliomas were found in 34 (77.2%) patients and in 87.5% of them they were located bilaterally.

Seventeen patients underwent surgeries.

Intracranial invasion with the involvement of the jugular foramen and destruction was observed in 12 cases (3 *SDHB*, 8 *SDHD*, 1 *SDHC*).

According to Shamblin classification, we assessed 47 carotid paragangliomas; 27 (57.4%) were classified as class I, 13 (27.7%) as class II and 7 (4.9%) as class III, the mean dimension in class I was 12.8±5.5 mm, in class II 13.4±9.8 mm, and in class III 29.6±13.6 mm.

We compared HNP of patients with *SDHB* and *SDHD* mutations.

There were no statistical differences in gender distribution and mean age between both groups. HNP were statistically more prevalent among *SDHD* compared with those with *SDHB* mutations (72.1% *vs.* 43.5%, p=0.033).

There was a significant difference in the prevalence of carotid paragangliomas between patients with *SDHB* and *SDHD* mutations (7/11 \[63.6%\] *vs.* 30/31 \[96.8%\], respectively, p=0.004). Patients with *SDHD* mutations more often had carotid paragangliomas located on the left side than on the right side as compared with *SDHB* mutations (25/31 *vs.* 4/11, p=0.006), but in both groups the prevalence of bilateral localization of carotid paragangliomas was similar (15/30 \[50.0%\] *vs.* 3/7 \[42.9%\], respectively, p=NS).

No statistical difference between both groups of *SDHx* mutations in the Shamblin classification was found ([Figure 3](#f3-poljradiol-81-510){ref-type="fig"}).

No marked differences between the prevalence of vagal, jugular and tympanic paragangliomas in terms of *SDHB* and *SDHD* mutations were found. The comparison of patients with *SDHB* and *SDHD* mutations is shown in [Table 3](#t3-poljradiol-81-510){ref-type="table"}.

Multiple tumors occurred in 32 patients, 6 out of 11 (54.5%) carriers with SDHB and 26 out of 31(83.9%) with *SDHD* mutations, p=0.05. Patients with *SDHD* mutations statistically more often revealed bilateral localization of HNP, 25/31 (80.6%) *vs.* 5/11 (45.5%) with *SDHB*, p=0.03.

Out of 72 patients with *SDHx* mutations, 7 patients (4 with *SDHB* and 3 with *SDHD* gene mutations) had a malignant disease with distant metastases to bones, liver, lungs and lymph nodes, and 6 of them had head and neck paragangliomas ([Figure 4A--4D](#f4-poljradiol-81-510){ref-type="fig"}). The carotid paragangliomas in patients with malignancy were in advanced stage (Shamblin classes II and III) compared to benign paragangliomas.

Discussion
==========

Among 72 patients with confirmed *SDHx* mutations we found HNP in 44 (61.1%) patients. The most common locations were carotid bifurcations and along the vagal nerves; moreover, paragangliomas were very often multifocal and bilateral.

HNP are uncommon tumors, which may occur sporadically or be associated with hereditary syndromes.

HNP are mostly benign, slowly enlarging tumors. Because of their location they may cause mass-effect symptoms with blood vessel and neural involvement, so early detection of paragangliomas may be crucial to increase the chance of cure with a lower morbidity rate. Different types of paragangliomas are connected with different clinical symptoms and prognosis. High tumor and skull-base involvement may cause nerve dysfunction after operation, therefore knowledge of the most frequent locations and differentiation with *SDHx*-related HNP may be clinically useful.

The most common mutation in our group was *SDHD* (61.1%), the rarest was *SDHC* (6.9%), which is in agreement with other authors \[[@b12-poljradiol-81-510]--[@b15-poljradiol-81-510]\]. The average age of patients in all group was 44±14.26 yrs, in groups of *SDHB* and *SDHD* mutations the mean age was similar. Head and neck paragangliomas were statistically more prevalent among *SDHD* mutation carriers (72.1%) compared with *SDHB* mutation carriers (43.5%), like in other studies \[[@b16-poljradiol-81-510],[@b17-poljradiol-81-510]\].

The majority of paragangliomas in the current study, like in other studies, were located in the carotid bifurcation \[[@b18-poljradiol-81-510],[@b19-poljradiol-81-510]\]. In our study, carotid paragangliomas significantly more commonly occurred in patients with *SDHD* mutations and were more often located on the left side. The Shamblin classification of carotid paragangliomas is still in use and some authors have shown a good correlation with surgical complications and outcomes \[[@b20-poljradiol-81-510]--[@b22-poljradiol-81-510]\]. Morbidity related to surgical resection (postoperative neurovascular complications) for Shamblin type III carotid body tumors is higher than for type I and II \[[@b23-poljradiol-81-510]\].

The majority of carotid paragangliomas in our study were classified as group I, but in patients with malignant carotid paragangliomas, they were in advanced stage (Shamblin classes II and III) compared to benign paragangliomas.

Ericson et al. reported that the second most common location of HNP was the jugular bulb, the least frequent were vagal paragangliomas, which represent less than 5% of all HNP \[[@b9-poljradiol-81-510],[@b24-poljradiol-81-510]--[@b26-poljradiol-81-510]\]. In our study, vagal paragangliomas were more frequent than jugular and tympanic paragangliomas and they represented 23.89% of all paragangliomas.

Nettervile et al. reported intracranial extension in 22% of vagal paragangliomas and in case of extension through the jugular foramen the vagal paraganglioma may cause the same symptoms as jugular paraganglioma \[[@b25-poljradiol-81-510]\]. The resection of vagal and jugular paragangliomas is related to a higher morbidity compared with carotid paragangliomas \[[@b27-poljradiol-81-510]\].

Paragangliomas have a tendency to occur multifocally, especially in familial lesions \[[@b27-poljradiol-81-510],[@b28-poljradiol-81-510]\]. Reports about hereditary paragangliomas indicate that 10--50% of patients have multiple tumors \[[@b26-poljradiol-81-510]\]. In our report, the prevalence of multifocal tumor was higher (77.2%) and 87.5% of them were located bilaterally.

In our study, patients with *SDHD* mutation significantly more commonly had multifocal paragangliomas than patients with *SDHB* mutations, as in the study by Neumann \[[@b16-poljradiol-81-510]\], 26 patients out of 31 with *SDHD* mutations in the present study had multifocal paragangliomas compared with 6 out of 11 patients with *SDHB* mutations \[[@b16-poljradiol-81-510]\]. The treatment of a multicentric disease is more complicated than in case of solitary paragangliomas \[[@b27-poljradiol-81-510]\].

Paragangliomas are mainly benign but some cases of malignant tumors have also been described. Several authors reported that the risk of malignance is higher in SDHB than in *SDHD* mutations \[[@b16-poljradiol-81-510],[@b28-poljradiol-81-510]\].

In our study, unlike in other studies, the prevalence of malignancy in both groups (*SDHB* and *SDHD)* was similar \[[@b16-poljradiol-81-510],[@b28-poljradiol-81-510]\].

Seven patients were diagnosed with a malignant disease with metastases to bones, liver, lung and lymph nodes. Lee et al. reported that in the head and neck area vagal paragangliomas were the most common (16--19%), the next location was carotid body paragangliomas (approximately 6%) followed by jugulotympanic paragangliomas (2--4%) \[[@b29-poljradiol-81-510]\]. In our study, patients with malignancies had multifocal head and neck paragangliomas, mostly located in different regions, while carotid paraganliomas were found in 4 patients, and vagal paragangliomas in 3 patients.

The carotid paragangliomas in patients with malignancy were in advanced stage (Shamblin classes II and III) compared to benign paragangliomas.

The optimal management of HNP depends on size, location, involvement of neurovascular structures, malignancy and multifocal locations \[[@b24-poljradiol-81-510]\]; therefore, early recognition is important.

Conclusions
===========

*SDHx* mutations predispose to multifocal and bilateral HNP. Carotid and vagal paragangliomas occurred most often.

Patients with *SDHD* mutations are characterized by higher frequency of head and neck paragangliomas than patients with *SDHB* mutations which is mainly caused by a higher frequency of carotid body tumors in patients with *SDHD* mutations. No difference in the frequency of head and neck paragangliomas in other locations was found.
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![Carotid paraganglioma in a 32-year-old man with *SDHD* mutation. Contrast-enhanced CT, sagittal view, MIP reconstruction shows an intensely-enhancing mass in the left carotid bifurcation (arrow).](poljradiol-81-510-g001){#f1-poljradiol-81-510}

![Vagal paraganglioma in a 47-year-old man with *SDHB* mutation. Contrast-enhanced CT, MIP reconstruction, sagittal view shows an enhancing mass (arrow) causing displacement of the internal carotid artery anteriorly.](poljradiol-81-510-g002){#f2-poljradiol-81-510}

![Comparison of carotid paragangliomas according Shamblin classification in patients with *SDHB* and *SDHD* mutations.](poljradiol-81-510-g003){#f3-poljradiol-81-510}

![A 37-year-old man with malignancy *SDHB* mutation. (**A, B**) Contrast-enhanced CT, a-coronal, b-axial view, showing well-enhanced tumor mass extending from the carotid bifurcation to the left tympanum (arrows). (**C, D**) CT, axial views show osteoblastic metastases to the thoracic vertebrae and to the left occipital and sphenoid bones (arrows).](poljradiol-81-510-g004){#f4-poljradiol-81-510}

###### 

Clinical characteristics of patients.

  Patient   Gender   Age   Gene mutation   Variants                                          Variants type    Index case/relative   HNP   Malignant
  --------- -------- ----- --------------- ------------------------------------------------- ---------------- --------------------- ----- -----------
  1\.       Female   52    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  2\.       Male     32    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  3\.       Male     25    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              Yes   No
  4\.       Male     22    SDHD            Exon2, c.112 C\>T, p.R38X                         Nonsense         Index                 Yes   No
  5\.       Female   50    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   Yes
  6\.       Male     40    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              Yes   No
  7\.       Male     25    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              Yes   No
  8\.       Male     25    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              Yes   No
  9         Female   38    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  10\.      Female   46    SDHD            Exon 1, c.33C\>A, p. C11X                         Missense         Index                 Yes   No
  11\.      Male     50    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Index                 Yes   No
  12\.      Male     43    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Relative              Yes   No
  13\.      Male     55    SDHB            Exon 7, c.650G\>T, p.R217L                        Missense         Index                 Yes   No
  14\.      Female   43    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  15\.      Female   30    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  16\.      Female   53    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   Yes
  17\.      Female   71    SDHC            Exon 4, c.214C\>T, p.R72C                         Missense         Index                 Yes   No
  18\.      Male     47    SDHB            Exon 7, c. 689 G\>T, p. R230L                     Missense         Index                 Yes   Yes
  19\.      Male     47    SDHD            Exon 3, c.274G\>T, p.D92Y                         Missense         Index                 Yes   No
  20\.      Male     55    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  21\.      Male     49    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  22\.      Male     38    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  23\.      Female   71    SDHC            Exon 4, c.214C\>T, p.R72C                         Missense         Index                 Yes   No
  24\.      Female   62    SDHB            Exon 6, c.574T\>C, p.C192R                        Missense         Relative              Yes   No
  25\.      Female   70    SDHB            Exon 6, c.574T\>C, p.C192R                        Missense         Index                 Yes   No
  26\.      Female   33    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  27\.      Male     31    SDHB            Exon 6, c.587G\>A, p.C196Y                        Missense         Index                 Yes   No
  28\.      Male     39    SDHD            Exon 2 c.112C\>T, p.R38X,                         Nonsense         Index                 Yes   No
  29\.      Male     47    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Relative              Yes   No
  30\.      Male     26    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Relative              Yes   No
  31\.      Female   44    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  32\.      Female   31    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  33\.      Female   49    SDHD            Exon 3, c.274G\>T, p.D92Y                         Nonsense         Relative              Yes   No
  34\.      Male     34    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  35\.      Male     64    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   Yes
  36\.      Male     59    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  37\.      Male     24    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 No    No
  38\.      Male     37    SDHB            Exon 3, c.268C\>T, p. R90X                        Nonsense         Index                 Yes   Yes
  39\.      Male     28    SDHB            Exon 6, c. 574 T\>C, p. C192R                     Missense         Index                 Yes   Yes
  40\.      Male     43    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  41\.      Female   46    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  42\.      Female   45    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  43\.      Female   23    SDHD            Exon 4 c.395C\>G, p.S132X                         Nonsense         Index                 No    No
  44\.      Male     32    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  45\.      Male     59    SDHC            Exon 4, c.214C\>T, p.R72C                         Missense         Relative              No    No
  46\.      Male     70    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  47\.      Female   35    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 No    No
  48\.      Male     66    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  49\.      Male     74    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Relative              No    No
  50\.      Female   33    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Relative              No    No
  51\.      Male     43    SDHB            Exon 7, c.650G\>T, p.R217L                        Missense         Relative              No    No
  52\.      Male     56    SDHB            Exon 7, c.650G\>T, p.R217L                        Missense         Relative              No    No
  53\.      Male     63    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  54\.      Female   63    SDHB            Exon 2, c.87_88insCAG, p.Ala29_Gln30insProfsX63   Frameshift       Index                 No    No
  55\.      Female   38    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 No    No
  56\.      Female   61    SDHB            Exon 6, c.574T\>C, p.C192R                        Missense         Relative              No    No
  57\.      Female   50    SDHB            Exon 6, c.587G\>A, p.C196Y                        Missense         Relative              No    No
  58\.      Female   34    SDHB            Exon 6, c.587G\>A, p.C196Y                        Missense         Index                 No    No
  59\.      Male     30    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  60\.      Female   23    SDHD            Exon 4 c.395C\>G, p.S132X                         Nonsense         Index                 No    No
  61\.      Female   45    SDHD            Exon 1 deletion                                   Large deletion   Index                 No    No
  62\.      Female   29    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              Yes   No
  63\.      Female   61    SDHD            exon2 c.112C\>T,p.R38X                            Nonsense         Index                 Yes   No
  64\.      Female   40    SDHB            Exon 1 deletion                                   Large deletion   Index                 No    Yes
  65\.      Male     64    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Index                 Yes   No
  66\.      Female   13    SDHB            Exon 7, c. 689 G\>T, p. R230L                     Missense         Relative              No    No
  67\.      Male     53    SDHC            Exon 3, c.78-2A\>G, p.splicesite alteration       Splicesite       Relative              No    No
  68\.      Male     28    SDHC            Exon 3, c.78-2A\>G, p.splicesite alteration       Splicesite       Relative              No    No
  69\.      Female   37    SDHD            Exon 1, c.33C\>A, p. C11X                         Nonsense         Relative              No    No
  70\.      Female   45    SDHB            Exon 5,c.530G\>A, p.R177H                         Missense         Index                 No    No
  71\.      Male     43    SDHD            Exon2, c.123C\>T, p.R38X                          Nonsense         Index                 Yes   No
  72\.      Female   27    SDHB            Exon 6, c.587G\>A, p.C196Y                        Missense         Relative              No    No

###### 

The number and locations of paragangliomas in patients with *SDHx* mutations.

              Carotid paraganglioma   Jugular paraganglioma   Vagal paraganglioma   Tympanic paraganglioma   Other location
  ----------- ----------------------- ----------------------- --------------------- ------------------------ ----------------
  HNP N=113   59 (52.21%)             14 (12.38%)             27 (23.89%)           11 (9.7%)                2 (1.8%)
  SDHB N=19   10                      2                       4                     1                        2
  SDHD N=90   48                      11                      23                    8                        0
  SDHC N=4    1                       1                       0                     2                        0

###### 

Comparison of patients with *SDHB* and *SDHD* mutations.

  -------------------------------------------------------------------
                    SDHB\                SDHD\                p
                    No. of patients 11   No. of patients 31   
  ----------------- -------------------- -------------------- -------
  Age (years)       45±15.3              42.25±12.8           0.43

  Male              9 (81.8%)            16 (51.6%)           0.069

  Carotid PGL       7 (63.6%)            30 (96.8%)           0.004

  Jugular PGL       2 (18.2%)            9 (29%)              0.48

  Vagal PGL         3 (27.3%)            14 (45.2%)           0.29

  Tympanic PGL      1 (9.1%)             7 (22.6%)            0.32

  Other PGL         2                                         

  Mulitifocal HNP   6 (54.5%)            26 (83.9)            0.05

  Bilateral HNP     5 (45.5%)            25 (80.6%)           0.026
  -------------------------------------------------------------------

P\<0.05 significant; No. -- number.
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